Zepbound® injection (tirzepatide) is a prescription medication approved for chronic weight management in adults with obesity, or in adults who are overweight with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. Zepbound is intended to be used together with a reduced-calorie diet and increased physical activity.
Tirzepatide works by mimicking the activity of two natural hormones, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones help regulate blood sugar, slow digestion, reduce appetite, and promote a feeling of fullness, supporting both improved metabolic control and sustained weight loss.
How to Use
-
Zepbound® is typically prescribed as a once-weekly subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm.
-
Treatment usually begins with a lower starting dose and is gradually increased to improve tolerability.
-
A common dosing approach begins at 2.5 mg once weekly, with stepwise increases every 4 weeks as directed by your healthcare provider, up to a maximum dose of 15 mg once weekly.
-
Injections should be given on the same day each week, with or without food.
-
Injection sites should be rotated with each dose, and a new needle should be used every time.
-
If a dose is missed, your healthcare provider will advise whether to take it when remembered or to wait until the next scheduled dose.
Black Box Warning
Zepbound® (tirzepatide) carries a boxed warning for the risk of thyroid C-cell tumors. It should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in those with multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients should promptly report symptoms such as a lump in the neck, hoarseness, difficulty swallowing, or shortness of breath.
Important Notes and Warnings
-
The most common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite, especially during dose escalation.
-
Serious but less common risks include pancreatitis, gallbladder disease, kidney injury (often related to dehydration), and possible worsening of diabetic retinopathy in patients with type 2 diabetes.
-
Zepbound should not be used with other GLP-1 receptor agonists or medications containing tirzepatide.
-
Not recommended during pregnancy; treatment should be discontinued at least 2 months before a planned pregnancy.
-
Inform your healthcare provider about all medications you are taking, as Zepbound may delay gastric emptying and affect absorption of certain oral drugs.
-
This medication is intended for long-term use as part of a comprehensive weight management program.